Evidence map›Paper›PMID 34003597›Full record

ArticlePharmacology research & perspectives2021

Prevalence and determinants of attention deficit/hyperactivity disorder (ADHD) medication use during pregnancy: Results from the Quebec Pregnancy/Children Cohort.

Maxim Lemelin, Takoua Boukhris, Jin-Ping Zhao, Odile Sheehy, Anick Bérard

Open access · goldAbstract read
In one paragraph

Article in Pharmacology research & perspectives, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Obstetric complications in mothers with ADHD.Frontiers in reproductive health · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Maxim LemelinFaculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.
Takoua BoukhrisFaculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.
Jin-Ping ZhaoResearch Center, CHU Sainte-Justine, Montreal, Quebec, Canada.
Odile SheehyResearch Center, CHU Sainte-Justine, Montreal, Quebec, Canada.
Anick BérardFaculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.ORCID 0000-0001-7535-5517
Centre Hospitalier Universitaire Sainte-Justine · CAUniversité de Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe use of attention deficit/hyperactivity disorder (ADHD) medications has grown over the past decade among pregnant women, but these treatments are not without risk. Updated prevalence of ADHD medication use and whether prescribed dosages follow guidelines are needed. The aim of this study is to describe the prevalence of ADHD medication use among pregnant women-dosages and switches-and identify determinants of ADHD medication use.

methodA population-based longitudinal cohort study within the Quebec Pregnancy/Children Cohort (QPC). Women aged 15-45 years old covered by the RAMQ prescription drug plan for at least 12 months before and during pregnancy from 1998 to 2015. ADHD medication exposure was assessed before and during pregnancy. We estimated odds ratios (ORs) for determinants of ADHD medication use during pregnancy with generalized estimating equations.

resultsAmong 428,505 included pregnant women, 1,130 (0.26%) used ADHD medication. A 14-fold increase in the prevalence of ADHD medication use in pregnant women was observed, from 1998 (0.08%) to 2015 (1.2%). Methylphenidate was the most prevalent medication at 70.1%. ADHD medication fillings were at optimal dosage 91.8% of the time based on guidelines and 18.1% of women switched to another ADHD medication class during gestation. Main determinants of ADHD medication use during pregnancy were psychiatric disorders (aOR 2.19; 95% confidence interval [CI] 1.57, 2.96), mood and anxiety disorders (aOR 1.74; 95% CI 1.32, 2.24), and calendar year.

conclusionsThe number of pregnancies exposed to ADHD medications has increased similarly to the increase reported in other countries between 1998 and 2015. In addition to the current literature, the use of ADHD medications during pregnancy is consistent with Canadian guidelines recommendations on dosage.

Indexed as

AdolescentAdrenergic Uptake InhibitorsAdultAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsCohort StudiesDrug UtilizationFemaleHumansMaternal-Fetal ExchangePregnancyPrevalenceQuebecYoung AdultAdrenergic Uptake InhibitorsAtomoxetine HydrochlorideCentral Nervous System Stimulantsattention deficit/hyperactivity disorders (ADHD)dosagemethylphenidatenon-stimulantspregnancyprenatal exposureprevalenceQuebec Pregnancy Cohortstimulants

Identifiers

PMID34003597
PMCPMC8130656
OpenAlexW3161839669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.